echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Clinical trial of AstraZeneca anticancer drug AZD5991 suspended due to cardiac safety risks

    Clinical trial of AstraZeneca anticancer drug AZD5991 suspended due to cardiac safety risks

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    According to an update on the clinical trial database (ClinicalTrials.


    In an interview with FierceBiotech, AstraZeneca stated that it had found signs of heart problems in a patient treated with AZD5991


    Therefore, AstraZeneca has stopped the treatment of patients in the trial and voluntarily suspended the trial


    An AstraZeneca spokesperson pointed out: "It is worth noting that the asymptomatic blood pressure increase has been resolved


    Two years ago, Amgen's blood cancer drug AMG 397 was also hindered by cardiac safety issues.


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.